anti-CD3/anti-TSLPR bispecific T-cell engager (University of Texas MD Anderson Cancer/Xencor)

N/A

Report date: 2026/03/19 16:53:16

Base Information

Drug Nameanti-CD3/anti-TSLPR bispecific T-cell engager (University of Texas MD Anderson Cancer/Xencor)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionT cell surface glycoprotein CD3 modulatorsCytokine receptor-like factor 2 modulatorsImmunostimulants +[4] 
TargetsCytokine receptor-like factor 2T cell surface glycoprotein CD3
Therapy Area/IndicationsPrecursor B-Cell Lymphoblastic Leukemia-LymphomaNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesThe University Of Texas MD Anderson Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesXencor IncThe University Of Texas MD Anderson Cancer Center
Inactive CompaniesN/A
Active IndicationsPrecursor B-Cell Lymphoblastic Leukemia-Lymphoma
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A